CAGR of 24.7% (2023 - 2031) | Rising Demand for Biosimilars Drives Growth in the Global Market | Pfizer, Biocon, Amgen, Novartis/Sandoz Celltrion

𝐓𝐨𝐩 𝐤𝐞𝐲 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲:

Pfizer
Biocon
Amgen
Novartis/Sandoz
Celltrion
Samsung Bioepis
Teva Pharmaceuticals
Boehringer Ingelheim
Mylan
Fresenius Kabi

These companies are involved in various aspects of the biosimilars industry, including research and development, manufacturing, and marketing of biosimilar drugs. They are key players in the industry, driving innovation, and competition in the market.

𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 $𝟏𝟓.𝟗 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟏, 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $𝟏𝟒𝟑.𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟏, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟐𝟒.𝟕% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟐 𝐭𝐨 𝟐𝟎𝟑𝟏.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭:

https://www.alliedmarketresearch.com/request-sample/162

Biosimilars are drugs that are similar to other biological medicines that have already been approved for use. Biological medicines are made from living organisms, such as cells or bacteria, and are used to treat many different diseases, such as cancer and autoimmune disorders.

Biosimilars are not exactly the same as the original biological medicine, but they are highly similar in terms of safety and effectiveness. They are developed to be as close as possible to the original biological medicine, while also being less expensive.

Like the original biological medicine, biosimilars must go through rigorous testing and regulatory approval before they can be used to treat patients. Once approved, they can provide patients with more affordable treatment options while maintaining the same level of safety and effectiveness as the original biological medicine.

𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐂𝐨𝐯𝐢𝐝-𝟏𝟗:

The COVID-19 pandemic created difficulties for the pharmaceutical industry to focus on R&D activities including biosimilar development, which impacted the global biosimilars market negatively.

Moreover, there was a delay in product approvals and product launches, owing to the global health crisis, which further restricted the expansion of the market.

𝐀𝐬𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐄𝐱𝐩𝐞𝐫𝐭:

https://www.alliedmarketresearch.com/request-for-customization/162?reqfor=covid

𝐓𝐡𝐞 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞𝐬 𝐬𝐞𝐯𝐞𝐫𝐚𝐥 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐬, 𝐢𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠:

Type of Product: This segment includes biosimilars for various types of biological medicines, such as monoclonal antibodies, insulin, erythropoietin, and growth hormones.

Application: This segment includes biosimilars used to treat various diseases, such as cancer, autoimmune disorders, infectious diseases, and others.

Distribution Channel: This segment includes the various channels through which biosimilars are distributed, such as hospitals, retail pharmacies, and online pharmacies.

Geography: This segment includes the different regions where biosimilars are available, such as North America, Europe, Asia Pacific, and Rest of the World.

End-user: This segment includes the various end-users of biosimilars, such as patients, hospitals, and clinics.

Understanding these segments is important for businesses operating in the biosimilars market to identify opportunities for growth, target specific customer groups, and develop effective marketing strategies.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭:

https://www.alliedmarketresearch.com/purchase-enquiry/162

𝐒𝐞𝐯𝐞𝐫𝐚𝐥 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐜𝐚𝐧 𝐢𝐦𝐩𝐚𝐜𝐭 𝐭𝐡𝐞 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐦𝐚𝐫𝐤𝐞𝐭, 𝐛𝐮𝐭 𝐡𝐞𝐫𝐞 𝐚𝐫𝐞 𝐬𝐨𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐭𝐨𝐩 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐭𝐡𝐚𝐭 𝐜𝐚𝐧 𝐡𝐚𝐯𝐞 𝐚 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭:

Patent Expiration: The expiration of patents on biologic drugs opens up opportunities for biosimilar manufacturers to enter the market and offer more affordable alternatives. This can lead to increased competition and a larger biosimilars market.

Cost-effectiveness: Biosimilars are generally less expensive than their reference biologic drugs, making them a cost-effective option for patients and healthcare providers. The cost-effectiveness of biosimilars can increase demand and drive market growth.

Regulatory Framework: The regulatory framework surrounding biosimilars is a critical factor in the market's growth. The regulatory requirements and processes for the approval of biosimilars vary across different countries, which can impact the market's growth in these regions.

Increasing Incidence of Chronic Diseases: The increasing incidence of chronic diseases such as cancer and autoimmune diseases is driving demand for biologic drugs, including biosimilars. This factor is expected to fuel market growth in the coming years.

Advancements in Biotechnology: Advances in biotechnology, including gene editing and cell therapy, are expected to impact the biosimilars market by creating new opportunities for biosimilar manufacturers to develop innovative products.

These factors are interrelated and can impact each other, leading to dynamic changes in the biosimilars market over time.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐫𝐞𝐩𝐨𝐫𝐭𝐬:

Medical Implant Market https://www.alliedmarketresearch.com/medical-implants-market

Oxygen Concentrators Market https://www.alliedmarketresearch.com/press-release/medical-oxygen-concentrators-market.html

RNA Based Therapeutic Market https://www.alliedmarketresearch.com/rna-based-therapeutics-market

Medical Fluid Bag Market https://www.alliedmarketresearch.com/medical-fluid-bags-market-A10872

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

This release was published on openPR.